Remove 2017 Remove FDA Remove Labelling
article thumbnail

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Fierce Pharma

With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. | The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease.

FDA 98
article thumbnail

FDA-Approved Labeling: Is Enough Enough?

The FDA Law Blog

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Finalizes Guidance Re Enforcement Policy for Homeopathic Drugs

The FDA Law Blog

By Riëtte van Laack — On December 7, 2022, FDA announced the availability of the final guidance regarding the enforcement policy for homeopathic drug products. This concludes FDA’s reevaluation of the regulation of homeopathic drugs which it started in 2015. It issued a draft guidance in 2017 which was subsequently revised in 2019.

FDA 98
article thumbnail

While the Orphan Battles Wages, Jazz Takes a Loss

The FDA Law Blog

Koblitz — The fight between Jazz, Avadel, and FDA over narcolepsy drug sodium oxybate has been a long and arduous one. Jazz argued that FDA’s determination was a violation of the Administrative Procedure Act on several fronts. Avadel intervened, and both FDA and Avadel refuted these assertions.

FDA 109
article thumbnail

Traditional Meat Industry’s Beef With Alternative Protein Continues with the FAIR on Labels Act

The FDA Law Blog

Many individual states have pursued some type of legislation to restrict the use of traditional meat terminology for the labeling of APPs. Many states have proposed but failed to enact legislation regulating the labeling of APPs, in some cases due to concerns of potential legal challenges based on federal preemption claims.

article thumbnail

The End of the Road for the Skinny Label?

The FDA Law Blog

We previously noted that “ the skinny label may be dead ” and, while we still can’t be sure if it’s truly gone (but not forgotten), we now know that the Supreme Court won’t hear this case at this time. Further, FDA, in its ministerial role, only looks at the use code and approves a carve-out based on the use code.

article thumbnail

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

pharmaphorum

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). The post Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia appeared first on.

FDA 115